Oseltamivir Phosphate (Tamiflu) CAS 204255-11-8 Assay 98.0%~101.5% API
Supply with High Purity and Stable Quality
Chemical Name: Oseltamivir Phosphate
CAS: 204255-11-8
API High Quality, Commercial Production
| Chemical Name | Oseltamivir Phosphate |
| Synonyms | Tamiflu |
| CAS Number | 204255-11-8 |
| CAT Number | RF-API87 |
| Stock Status | In Stock, Production Scale Up to Hundreds of Kilograms |
| Molecular Formula | C16H31N2O8P |
| Molecular Weight | 410.4 |
| Melting Point | 196.0 to 198.0℃ |
| Storage Temperature | 2-8℃ |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Crystalline Powder |
| Identification | IR, HPLC |
| Assay | 98.0%~101.5% (HPLC on the anhydrous basis) |
| Water Content (by K.F) | ≤0.50% |
| Specific Optical Rotation | -30.7° to -32.6° (C=1 in H2O) |
| Related Substances 1 | (HPLC) |
| Oseltamivir Acid | ≤0.30% |
| Oseltamivir Pheol | ≤0.10% |
| Any Unspecified Impurity | ≤0.10% |
| Total Impurities | ≤0.40% |
| Related Substances 2 | Oseltamivir Related Compound A ≤0.01% (HPLC-MS) |
| Related Substances 3 | Tributyl Phosphine ≤0.10% (GC) |
| Heavy Metals | ≤10ppm |
| Residue on Ignition | ≤0.20% |
| Heavy Metals | ≤20ppm |
| Shelf Life | 24 Months |
| Test Standard | Enterprise Standard; United States Pharmacopoeia (USP) Standard |
| Usage | API, Orally active inhibitor of influenza virus neuraminidase |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
Oseltamivir Phosphate is an orally active inhibitor of influenza virus neuraminidase; converted in vivo to the active acid metabolite. An antiviral drug. It is a COVID19-related research product. Oseltamivir phosphate is a kind of anti-influenza drugs, under the trade name Tamiflu. Oseltamivir was launched in the US and Switzerland for the treatment of influenza infections by all common strain viruses. Oseltamivir emerged as one of the first two neuraminidase inhibitors to reach the market. Oseltamivir was approved as the first orally administered neuraminidase inhibitor used against influenza A and B viruses. The drug is indicated for the treatment of uncomplicated acute illness caused by influenza infection.
